CHO-gmt5, a novel CHO glycosylation mutant for producing afucosylated and asialylated recombinant antibodies

Bioengineered

Volumn 4, Issue 2, 2013, Pages 90-94

  Haryadi, Ryan ^a   Zhang, Peiqing ^a   Chan, Kah Fai ^a   Song, Zhiwei ^a  

^a AGENCY FOR SCIENCE   (Singapore)

Author keywords

Antibody dependent cell mediated cytotoxicity (ADCC); CHO cells; CMP sialic acid transporter; GDP fucose transporter; Recombinant antibodies; Zinc finger nucleases (ZFNs)

Indexed keywords

AFUCOSYLATED RECOMBINANT ANTIBODY; ASIALYLATED RECOMBINANT ANTIBODY; CYTIDINE PHOSPHATE; DIHYDROFOLATE REDUCTASE; GUANOSINE DIPHOSPHATE; IMMUNOGLOBULIN G1; LECTIN; RECOMBINANT ANTIBODY; SIALIC ACID; UNCLASSIFIED DRUG; ZINC FINGER NUCLEASE; ANTIBODY; FUCOSE; GLUCOSE TRANSPORTER; GLYCOPROTEIN; N ACETYLNEURAMINIC ACID; NUCLEOTIDE TRANSPORTER; RECOMBINANT PROTEIN; SLC35A1 PROTEIN, HUMAN; SLC35C1 PROTEIN, HUMAN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ARTICLE; CHO CELL; FLUORESCENCE ACTIVATED CELL SORTING; GLYCOSYLATION; HUMAN; MUTANT; NONHUMAN; ANIMAL; ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC); CHEMISTRY; CMP-SIALIC ACID TRANSPORTER; GDP-FUCOSE TRANSPORTER; GENETICS; HAMSTER; METABOLISM; RECOMBINANT ANTIBODIES; ZINC-FINGER NUCLEASES (ZFNS);

ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC); CHO CELLS; CMP-SIALIC ACID TRANSPORTER; GDP-FUCOSE TRANSPORTER; RECOMBINANT ANTIBODIES; ZINC-FINGER NUCLEASES (ZFNS);

ANIMALS; ANTIBODIES; CHO CELLS; CRICETINAE; FUCOSE; GLYCOPROTEINS; GLYCOSYLATION; MONOSACCHARIDE TRANSPORT PROTEINS; N-ACETYLNEURAMINIC ACID; NUCLEOTIDE TRANSPORT PROTEINS; RECOMBINANT PROTEINS;

EID: 84877718637     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bioe.22262     Document Type: Article

References (30)

1. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000; 406:267-73; PMID:10917521; http://dx.doi. org/10.1038/35018508.
2. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 2001; 276:16469-77; PMID:11297532; http://dx.doi. org/10.1074/jbc.M100350200.
3. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003; 325:979-89; PMID:12527303; http://dx.doi.org/10.1016/S0022-2836(02)01250-0.
4. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200.
5. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi. org/10.1074/jbc.M210665200.
6. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 2004; 336:1239-49; PMID:15037082; http://dx.doi.org/10.1016/j.jmb.2004.01.007.
7. Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, Otaki S, et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 2007; 368:767-79; PMID:17368483; http://dx.doi.org/10.1016/j. jmb.2007.02.034.
8. Radaev S, Sun P. Recognition of immunoglobulins by Fcgamma receptors. Mol Immunol 2002; 38:1073-83; PMID:11955599; http://dx.doi.org/10.1016/S0161-5890(02)00036-6.
9. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64:2127-33; PMID:15026353; http://dx.doi.org/10.1158/0008-5472.CAN-03-2068.
10. Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, et al. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res 2007; 13:1875-82; PMID:17363544; http://dx.doi.org/10.1158/1078-0432.CCR-06-1335.
11. Cardarelli PM, Moldovan-Loomis MC, Preston B, Black A, Passmore D, Chen TH, et al. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res 2009; 15:3376-83; PMID:19401346; http://dx.doi. org/10.1158/1078-0432.CCR-08-3222.
12. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 2010; 70:4481-9; PMID:20484044; http://dx.doi.org/10.1158/0008-5472.CAN-09-3704.
13. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320:373-6; PMID:18420934; http://dx.doi.org/10.1126/science.1154315.
14. Kaneko Y, Nimmerjahn F, Ravetch JV. Antiinflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-3; PMID:16888140; http://dx.doi.org/10.1126/science. 1129594.
15. Lim SF, Lee MM, Zhang P, Song Z. The Golgi CMPsialic acid transporter: A new CHO mutant provides functional insights. Glycobiology 2008; 18:851-60; PMID:18713811; http://dx.doi.org/10.1093/glycob/cwn080.
16. Zhang P, Haryadi R, Chan KF, Teo G, Goh J, Pereira NA, et al. Identification of functional elements of the GDP-fucose transporter SLC35C1 using a novel Chinese hamster ovary mutant. Glycobiology 2012; 22:897-911; PMID:22492235; http://dx.doi. org/10.1093/glycob/cws064.
17. Chan KF, Zhang P, Song Z. Identification of essential amino acid residues in the hydrophilic loop regions of the CMP-sialic acid transporter and UDPgalactose transporter. Glycobiology 2010; 20:689-701; PMID:20181793; http://dx.doi.org/10.1093/glycob/cwq016.
18. Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony RM, Eichtinger M, et al. Rapid "opensource" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 2008; 31:294-301; PMID:18657511; http://dx.doi. org/10.1016/j.molcel.2008.06.016.
19. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435:646-51; PMID:15806097; http://dx.doi.org/10.1038/nature03556.
20. Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah GE, et al. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 2008; 26:702-8; PMID:18500334; http://dx.doi.org/10.1038/nbt1409.
21. Santiago Y, Chan E, Liu PQ, Orlando S, Zhang L, Urnov FD, et al. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci U S A 2008; 105:5809-14; PMID:18359850; http://dx.doi.org/10.1073/pnas.0800940105.
22. Carroll D, Morton JJ, Beumer KJ, Segal DJ. Design, construction and in vitro testing of zinc finger nucleases. Nat Protoc 2006; 1:1329-41; PMID:17406419; http://dx.doi.org/10.1038/nprot.2006.231.
23. Kim HJ, Lee HJ, Kim H, Cho SW, Kim JS. Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Res 2009; 19:1279-88; PMID:19470664; http://dx.doi. org/10.1101/gr.089417.108.
24. Sander JD, Zaback P, Joung JK, Voytas DF, Dobbs D. Zinc Finger Targeter (ZiFiT): an engineered zinc finger/target site design tool. Nucleic Acids Res 2007; 35(Web Server issue):W599-605; PMID:17526515; http://dx.doi.org/10.1093/nar/gkm349.
25. Dreier B, Segal DJ, Barbas CF 3rd. Insights into the molecular recognition of the 5'-GNN-3' family of DNA sequences by zinc finger domains. J Mol Biol 2000; 303:489-502; PMID:11054286; http://dx.doi. org/10.1006/jmbi.2000.4133.
26. Liu Q, Xia Z, Zhong X, Case CC. Validated zinc finger protein designs for all 16 GNN DNA triplet targets. J Biol Chem 2002; 277:3850-6; PMID:11726671; http://dx.doi.org/10.1074/jbc.M110669200.
27. Segal DJ, Dreier B, Beerli RR, Barbas CF 3rd. Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5'-GNN-3' DNA target sequences. Proc Natl Acad Sci U S A 1999; 96:2758-63; PMID:10077584; http://dx.doi.org/10.1073/pnas.96.6.2758.
28. Lee HJ, Kim E, Kim JS. Targeted chromosomal deletions in human cells using zinc finger nucleases. Genome Res 2010; 20:81-9; PMID:19952142; http://dx.doi.org/10.1101/gr.099747.109.
29. Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 2007; 25:778-85; PMID:17603475; http://dx.doi.org/10.1038/nbt1319.
30. Gaudray P, Trotter J, Wahl GM. Fluorescent methotrexate labeling and flow cytometric analysis of cells containing low levels of dihydrofolate reductase. J Biol Chem 1986; 261:6285-92; PMID:3700393.